Combination therapy could extend the current therapeutic time window of t-PA from 4.5 h and reduce adverse effects such as intracerebral hemorrhage (Jiang et al. 2015; Knecht et al. 2018). The gene discussed is PLAT; the disease is intracerebral hemorrhage.